huMNC2-CAR44

huMNC2-CAR44 is an autologous chimeric antigen receptor (CAR) T cell therapy developed by Minerva Biotechnologies for the treatment of MUC1* positive cancers, primarily metastatic breast cancer. The therapy involves isolating a patient's own T cells and genetically modifying them with a lentiviral vector to express a humanized single-chain variable fragment (scFv) that specifically targets the cleaved form of mucin 1 (MUC1*), which acts as a growth factor receptor and is present on approximately 90% of breast tumors. The construct includes human hinge and transmembrane domains, as well as costimulatory domains from 4-1BB and CD3-zeta. Preclinical studies have shown that these engineered T cells selectively kill MUC1* positive tumor cells without affecting normal tissues or full-length MUC1 expressing cells. Clinical trials are ongoing to evaluate safety and antitumor activity in patients with metastatic breast cancer[1][5][6].

Other names

CAR T therapeutics - Minerva